MNOV Stock In Focus As COMBAT-ALS Completes Double-Blind Phase; Results Due By Year-End

MediciNova completed the last patient, last visit in the double-blind portion of its Phase 2b/3 COMBAT-ALS trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis. The milestone advances the program toward data analysis and potential topline results, representing a modestly positive catalyst for MNOV.